BNET Industries
Celgene Corp. (CELG) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $1.4B
- Profit
- Dec 31 2007
- $226.4M
- Market Cap
- Aug 27 2008
- $32.2B
Latest News and Analysis
My Model Biotech Picks: What's Hot and What's Not
A. Reza Saadat submits: Analyzing the performance of my previous picks is by far my favorite part of writing this blog. It has on many occasions allowed be to learn from my mistakes.I have moved the numbers to Google docs so that they are easier to read. Here is...
The Long Case for Celgene Corp.
Steve Patterson submits: Medical Stocks have been showing continued strength with the overall market uncertain if the correction has ended or the current uptrend is just a pause before another leg down for the markets. Celgene Corp. CELG is one of the strongest of the medical/biological companies that should continue...
KV Pharmaceutical's Motion for Rule 11 Sanctions in Ritalin LA Case Denied
Aaron F. Barkoff submits: Celgene and Novartis v. KV Pharm., No. 07-4819 (D.N.J. 2008) KV Pharmaceutical KVA filed an ANDA for a generic version of Ritalin LA (methylphenidate HCl extended-release capsules) with paragraph IV certifications to Celgene's CELG U.S. Patent Nos. 5,837,284 and 6,635,284. Apparently KV made an...
S&P 500's Best and Worst Net Income Change
Richard Shaw QVM Group submits: The vast majority of S&P 500 companies proxy SPY or IVV are profitable on a 12-month basis, but some have profits strongly on the rise and others have profits strongly on the fall. This article presents the 20 companies with the highest ratio...
Celgene Corp. Q2 2008 Earnings Call Transcript
Celgene Corporation CELG Q2 FY08 Earnings Call
Zacks Analyst Interview Highlights: Celgene, Regeneron, Myriad Genetics, Alkermes and Trimeris
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Celgene (Nasdaq: CELG), Regeneron (Nasdaq: REGN), Myriad Genetics (Nasdaq: MYGN), Alkermes (Nasdaq: ALKS) and Trimeris (Nasdaq: TRMS).
Celgene Corporation to Present at Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on Wednesday, June 11, 2008 at 10:00 a.m. EDT will be webcast live and will be available in the investor relations section of the Company's Web...
Celgene Corporation to Present at Goldman Sachs 29th Annual Global Healthcare Conference
SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Goldman Sachs 29th Annual Global Healthcare Conference on Wednesday, June 11th, 2008 at 10:00 a.m. PDT will be webcast live and will be available in the investor relations section of the Company's Web site at www.celgene.com. Sol...
Zacks Analyst Interview Highlights: Celgene, Regeneron, Myriad Genetics, Alkermes and Trimeris
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Celgene (Nasdaq: CELG), Regeneron (Nasdaq: REGN), Myriad Genetics (Nasdaq: MYGN), Alkermes (Nasdaq: ALKS) and Trimeris (Nasdaq: TRMS).
Celgene Corporation to Present at FBR Capital Markets Spring Investor Conference
SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the FBR Capital Markets Spring Investor Conference on Wednesday, May 28, 2008 at 11:15 a.m. EDT will be webcast live and will be available in the investor relations section of the Company's Web site at www.celgene.com. Perry Karsen,...
New Analyst Reports for CELGENE CORP, TOWER SEMICONDUCTOR LTD, YRC WORLDWIDE INC, and SBA COMMUNICATIONS
MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for CELGENE...
75 Abstracts Evaluating Celgene Products to Be Presented at The 44th American Society of Clinical Oncology Meeting
SUMMIT, N.J. -- Celgene Corporation (NASDAQ: CELG) today announced that clinical investigators from leading cancer research centers will present data from recent and on-going clinical trials of multiple Celgene products in blood cancers and solid tumors at the 44th American Society of Clinical Oncology ASCO Meeting in Chicago, Illinois from...
Celgene Corp. Q1 2008 Earnings Call Transcript
Celgene Corp. Q1 2008 Earnings Call Transcript
Celgene Reports Record First Quarter 2008 Product Sales and Operating Profits
SUMMIT, N.J. -- 2008 First Quarter Financial Results Year-Over-Year
MethylGene Provides Update on its MGCD0103 HDAC Inhibitor Collaboration With Celgene
MethylGene Inc. (TSX: MYG) announces that MethylGene and Celgene Corporation intend to advance the development of MGCD0103 during 2008. The companies are working together to advance several MGCD0103 programs including acute myelogenous leukemia, Hodgkin disease, myelodysplastic syndromes and solid tumor cancers following the acquisition of Pharmion Corporation by Celgene. As...
Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration
CAMBRIDGE, Mass. -- Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced it has received the upfront payment from Celgene Corporation following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the collaboration between the two companies...
Zacks Analyst Interview Highlights: Celgene, BioMarin, Myriad Genetics, Alkermes and Inspire Pharmaceuticals
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Celgene (Nasdaq: CELG), BioMarin (Nasdaq: BMRN), Myriad Genetics (Nasdaq: MYGN), Alkermes (Nasdaq: ALKS) and Inspire Pharmaceuticals Inc. (Nasdaq: ISPH).
Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
CAMBRIDGE, Mass. & SUMMIT, N.J. -- Acceleron Pharma, Inc. and Celgene Corporation today announced a worldwide strategic collaboration for the joint development and commercialization of ACE-011, a first-in-class, novel bone-forming compound. The collaboration combines both companies' resources and commitment to developing products for the treatment of cancer and cancer-related bone...
Celgene Corp. F1Q08 (Qtr. End 12/31/07) Earnings Call Transcript
Celgene Corp. F1Q08 (Qtr. End 12/31/07) Earnings Call Transcript
Clinical Data Reported on Celgene Compound Apremilast Evaluating Efficacy, Safety and Quality of Life Improvement for Psoriasis Patients
Updated results presented at 66th American Academy of Dermatology Meeting
- Next »
- page 1 of 7
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- stock (14 results)
- Call Transcript (11 results)
- Earnings (11 results)
- Seeking Alpha (11 results)
- Financial Accounting (11 results)
- Finance (11 results)
- biotechnology (9 results)
- Nasdaq Stock Market Inc. (7 results)
- health care (6 results)
- blog (5 results)
- Company (5 results)
- operating profit (5 results)
- Biotech (3 results)
- Apple Inc. (3 results)
- Merrill Lynch & Co. Inc. (3 results)
- Amgen Inc. (3 results)
- Incorporated: 1986
- CEO: Dr. Sol J. Barer Ph.D.
- Employees: 1,685
Celgene is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory diseases through regulation of cellular, genomic and proteomic targets. At Dec 31 2007, Co.'s key commercial stage products are REVLIMID® (lenalidomide), for treatment in combination with dexamethasone for multiple myeloma, and THALOMID® (thalidomide), for treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma and cutaneous manifestations of erythema nodosum leprosum. Co. also sells ALKERAN®, through a supply and distribution agreement with GlaxoSmithKline, and FOCALIN?, to Novartis Pharma AG.
Key Competitors
Celgene Corp. Company Info
Board of Directors
Dr. Sol J. Barer Ph.D.
Chairman
Mr. Robert J. Hugin
Mr. Michael D. Casey
Mr. Rodman L. Drake
Dr. Arthur Hull Hayes Jr.
Dr. Gilla Kaplan Ph.D.
Mr. James J. Loughlin
Dr. Ernest Mario Ph.D.
Dr. Walter L. Robb Ph.D.
Contact Information
86 Morris Avenue
Summit, NJ
908 673-9000
NAICS Code
Pharmaceutical and Medicine Manufacturing: 32541
